140 related articles for article (PubMed ID: 27008827)
21. Individual variations in treatment decisions by Swedish rheumatologists regarding biological drugs for rheumatoid arthritis.
Kalkan A; Hallert E; Carlsson P; Roback K; Sjöwall C
Scand J Rheumatol; 2015; 44(4):265-70. PubMed ID: 26202443
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of biologics in erythrodermic psoriasis: a multicentre, retrospective study.
Viguier M; Pagès C; Aubin F; Delaporte E; Descamps V; Lok C; Beylot-Barry M; Séneschal J; Dubertret L; Morand JJ; Dréno B; Bachelez H;
Br J Dermatol; 2012 Aug; 167(2):417-23. PubMed ID: 22413927
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials.
Reich K; Burden AD; Eaton JN; Hawkins NS
Br J Dermatol; 2012 Jan; 166(1):179-88. PubMed ID: 21910698
[TBL] [Abstract][Full Text] [Related]
24. Serum zinc/copper ratio in subtypes of leprosy and effect of oral zinc therapy on reactional states.
George J; Bhatia VN; Balakrishnan S; Ramu G
Int J Lepr Other Mycobact Dis; 1991 Mar; 59(1):20-4. PubMed ID: 2030313
[TBL] [Abstract][Full Text] [Related]
25. Switching of biologics in psoriasis: Reasons and results.
Honda H; Umezawa Y; Kikuchi S; Yanaba K; Fukuchi O; Ito T; Nobeyama Y; Asahina A; Nakagawa H
J Dermatol; 2017 Sep; 44(9):1015-1019. PubMed ID: 28488283
[TBL] [Abstract][Full Text] [Related]
26. Real-world treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriasis.
Wu JJ; Pelletier C; Ung B; Tian M
J Med Econ; 2019 Apr; 22(4):365-371. PubMed ID: 30652520
[TBL] [Abstract][Full Text] [Related]
27. Healthcare Provider Type and Switch to Biologics in Psoriasis: Evidence from Real-World Practice.
Calara PS; Norlin JM; Althin R; Carlsson KS; Schmitt-Egenolf M
BioDrugs; 2016 Apr; 30(2):145-51. PubMed ID: 26883786
[TBL] [Abstract][Full Text] [Related]
28. [Biologics and further new drugs for rheumatic diseases since 2000].
Krüger K
Orthopade; 2018 Nov; 47(11):906-911. PubMed ID: 30280235
[TBL] [Abstract][Full Text] [Related]
29. Biologic and Conventional Systemic Therapies Show Similar Safety and Efficacy in Elderly and Adult Patients With Moderate to Severe Psoriasis.
Garber C; Plotnikova N; Au SC; Sorensen EP; Gottlieb A
J Drugs Dermatol; 2015 Aug; 14(8):846-52. PubMed ID: 26267729
[TBL] [Abstract][Full Text] [Related]
30. Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany.
Li N; Betts KA; Messali AJ; Skup M; Garg V
Clin Ther; 2017 Aug; 39(8):1618-1627. PubMed ID: 28729087
[TBL] [Abstract][Full Text] [Related]
31. Recommendations for managing a suboptimal response to biologics for moderate-to-severe psoriasis: A Belgian perspective.
de la Brassinne M; Ghislain PD; Lambert JL; Lambert J; Segaert S; Willaert F
J Dermatolog Treat; 2016; 27(2):128-33. PubMed ID: 26415615
[TBL] [Abstract][Full Text] [Related]
32. Effect of additional administration of tacrolimus in patients with rheumatoid arthritis treated with biologics.
Miyata M; Asano T; Satoh S
Fukushima J Med Sci; 2011; 57(2):54-9. PubMed ID: 22353651
[TBL] [Abstract][Full Text] [Related]
33. No increased mortality in patients with rheumatoid arthritis treated with biologics: results from the biologics register of six rheumatology institutes in Japan.
Nakajima A; Saito K; Kojima T; Amano K; Yoshio T; Fukuda W; Inoue E; Taniguchi A; Momohara S; Minota S; Takeuchi T; Ishiguro N; Tanaka Y; Yamanaka H
Mod Rheumatol; 2013 Sep; 23(5):945-52. PubMed ID: 23073692
[TBL] [Abstract][Full Text] [Related]
34. [Discussion meeting on treatment of rheumatoid arthritis with biologics and their side effects].
Yamamoto K; Mimori T; Shinohara S; Hirabayashi Y; Nakachi S
Nihon Naika Gakkai Zasshi; 2011 Oct; 100(10):2998-3017. PubMed ID: 22175144
[No Abstract] [Full Text] [Related]
35. Immunology Update: Biologics.
Starr SP
FP Essent; 2016 Nov; 450():11-21. PubMed ID: 27869438
[TBL] [Abstract][Full Text] [Related]
36. The biologics of ulcerative colitis.
Macaluso FS; Renna S; Orlando A; Cottone M
Expert Opin Biol Ther; 2017 Feb; 17(2):175-184. PubMed ID: 27960557
[TBL] [Abstract][Full Text] [Related]
37. Estimating effectiveness and cost of biologics for rheumatoid arthritis: application of a validated algorithm to commercial insurance claims.
Curtis JR; Schabert VF; Harrison DJ; Yeaw J; Korn JR; Quach C; Yun H; Joseph GJ; Collier DH
Clin Ther; 2014 Jul; 36(7):996-1004. PubMed ID: 25012729
[TBL] [Abstract][Full Text] [Related]
38. A Case of Psoriasis Complicated by Breast Cancer after Systemic Treatments Including Biologics.
Morizane S; Sugimoto S; Motoki T; Katayama N; Omori M; Iwatsuki K
Acta Med Okayama; 2018 Apr; 72(2):185-187. PubMed ID: 29674768
[TBL] [Abstract][Full Text] [Related]
39. Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
Cantini F; Niccoli L; Nannini C; Cassarà E; Kaloudi O; Giulio Favalli E; Becciolini A; Benucci M; Gobbi FL; Guiducci S; Foti R; Mosca M; Goletti D
Semin Arthritis Rheum; 2017 Oct; 47(2):183-192. PubMed ID: 28413099
[TBL] [Abstract][Full Text] [Related]
40. Satisfaction of treatment with biologics is high in psoriasis: results from the Bio-CAPTURE network.
van den Reek JM; van Lüumig PP; Otero ME; Zweegers J; van de Kerkhof PC; Ossenkoppele PM; Njoo MD; Mommers JM; Koetsier MI; Arnold WP; Sybrandy-Fleuren BA; Kuijpers AL; Andriessen MP; Seyger MM; Kievit W; de Jong EM
Br J Dermatol; 2014 May; 170(5):1158-65. PubMed ID: 24484403
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
